Chronic kidney disease progression
1 paper1 finding
- Humans1
Associations
1Clonal hematopoiesis of indeterminate potential
upin humans1HR 2.2
1 study
Clonal hematopoiesis of indeterminate potential
upin humans1HR 2.2
Clonal hematopoiesis of indeterminate potential raises the risk of chronic kidney disease progression in humans (HR 2.2, 95% CI 1.2–3.8).
“Individuals with CHIP manifested a 2.2-fold increased risk of a 50% decline in eGFR or ESKD over 5 years of follow-up (hazard ratio 2.2; 95% confidence interval, 1.2 to 3.8)”
Humanspreexisting chronic kidney disease5 years
Journal of the American Society of Nephrology : JASN23 Feb 2022
Funding
1 grant since 2023National Institute of Diabetes and Digestive and Kidney DiseasesUS$868.9k
Latest
9 in 12 monthsNatural Resources for Human Health
MIRA-Net: A Missingness-Informed Residual Attention Network for Chronic Kidney Disease Prediction
Computational studyChronic kidney disease
American Journal of Cardiovascular Drugs
SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy
ReviewSGLT2 inhibitors
Frontiers in Pharmacology
Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis
Meta-analysis of randomised trialsSGLT2 inhibitors
medRxiv
A kidney-conditioned urinary peptidomic biological ageing clock predicts all-cause mortality and age-related health outcomes
Preprint: cohort study of 7,798 peopleBiomarkers
Life Sciences
Somatic genomic mosaicism in chronic kidney disease progression: A graded appraisal of renal epithelial injury, cellular senescence, and therapeutic implications
Systematic review of observational studiesKidney
American Journal of Physiology Renal Physiology
Dapagliflozin, in addition to ramipril, ameliorates kidney disease progression in mice with Alport syndrome
Experiments in miceDapagliflozin